Table II.
Morphea treatment. Respondents’ preferred first-line treatments.
| Treatment | Dermatologist, % | Pediatric Dermatologist, % | Rheumatologist, % | Pediatric Rheumatologist, % | p-value (bold if < 0.05) |
|---|---|---|---|---|---|
| Plaque morphea | |||||
| Methotrexate | 0 | 2.1 | 22.2 | 34.6 | 0.0272 |
| Methotrexate + systemic steroids | 0 | 2.1 | 11.1 | 13.5 | < 0.0001 |
| Systemic steroids | 0 | 0 | 0 | 3.8 | 0.1882 |
| Antimalarials/antibiotics | 2.5 | 0 | 19.4 | 3.8 | 0.0009 |
| Topical steroids | 92.5 | 74.5 | 22.2 | 21.2 | < 0.0001 |
| Phototherapy | 0 | 2.1 | 0 | 0 | 0.4336 |
| Linear morphea (including En Coup de Sabre and Parry-Romberg | |||||
| Methotrexate | 15.0 | 21.3 | 13.9 | 46.2 | < 0.0001 |
| Methotrexate + systemic steroids | 15.0 | 57.4 | 8.3 | 38.5 | 0.0007 |
| Systemic steroids | 7.5 | 0 | 2.8 | 11.5 | 0.0740 |
| Antimalarials/antibiotics | 5.0 | 0 | 5.6 | 0 | 0.1473 |
| Topical steroids | 22.5 | 10.6 | 2.8 | 1.9 | 0.0033 |
| Phototherapy | 2.5 | 8.5 | 0 | 0 | 0.0456 |
| Generalized morphea | |||||
| Methotrexate | 15.0 | 23.4 | 19.4 | 42.3 | 0.0142 |
| Methotrexate + systemic steroids | 7.5 | 38.3 | 30.6 | 34.6 | 0.0078 |
| Systemic steroids | 10.0 | 2.1 | 16.7 | 11.5 | 0.1531 |
| Antimalarials/antibiotics | 10.0 | 4.3 | 5.6 | 1.9 | 0.3723 |
| Topical steroids | 10.0 | 6.4 | 2.8 | 1.9 | 0.3080 |
| Phototherapy | 20.0 | 10.6 | 0 | 0 | 0.0007 |
Dermatologist: n = 40
Pediatric Dermatologist: n = 47
Rheumatologist: n = 36
Pediatric Rheumatologist: n = 52